Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy

Jan 23 2018

• By Mandy Jackson

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

Related Content

The Next Challenge: Improving And Predicting Responses As CAR-T Therapies Advance

Dec 29 2017

Celgene's CAR-T Leadership Goals Advance At ASH 2017

Dec 12 2017

Celgene's Partnered Pipeline Delivers Successes And Setbacks

Nov 21 2017

Blow For Celgene As Revlimid Trial Miss Removes Blockbuster Indication

Jul 26 2016

What's Gilead Getting From Kite For Nearly $12bn?

Aug 29 2017

Celgene Revamps IO Deal With Emerging Biotech Sutro; Takeover Option Removed

Aug 11 2017

Celgene shows CAR-T confidence with $1bn Juno investment

Jun 30 2015

Should Celgene Succumb To The Charms Of Juno?

Jan 17 2018

Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond

Jan 09 2018

Related Companies

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Bluebird Bio

Impact Biomedicines, Inc.

Novartis AG

Gilead Sciences, Inc.

Kite Pharma, Inc.

Roche Holding AG

AbbVie Inc.

Johnson & Johnson

Sutro Biopharma, Inc.

Additional Topics

M & A Business Strategies ImmunoOncology Deals Commercial BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.